Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara White

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Arthritis and Rheumatism|November 30, 2006
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertensionLionel Schachna, Thomas A Medsger, James H Dauber, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
NEJM Evidence|February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryDeepak L Bhatt, Charles V Pollack, C David Mazer, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2025
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosisNatalie E West, Michael W Konstan, Patrick A Flume, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Arthritis and Rheumatism|November 30, 2006
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertensionLionel Schachna, Thomas A Medsger, James H Dauber, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
NEJM Evidence|February 6, 2024
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryDeepak L Bhatt, Charles V Pollack, C David Mazer, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2025
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosisNatalie E West, Michael W Konstan, Patrick A Flume, et al.
Arthritis and Rheumatism|November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco, Michael H Weisman, James R Seibold, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Pageof 8